Le Goaster J, Houyez F, Frances C, Courpotin C, Lasfargues G, Dormont D; International Conference on AIDS.
Int Conf AIDS. 1993 Jun 6-11; 9: 494 (abstract no. PO-B28-2156).
Hop. Trousseau Paris, France.
OBJECTIVE: Phase I evaluation of the safety and efficacy of orally administrated derived pyran molecule in a small group of HIV infected patients. RATIONALE: Following our evaluation of early neuro-hormonal disorders of ACTH/B Endorphins and ACTH/Cortisol total ratios related to the HIV infection, we speculated an early viral impact on the neuroimmunological modulation through the ProOpioMelanoCortin (P.O.M.C) gene and we chose to screen a pyran molecule able to interfere with the regulation of the P.O.M.C gene expression. METHODS AND RESULTS: Therefore 10 patients were treated with the derived pyran molecule, 40 mg/day x 3 weeks and 40 mg/day x 2 days/week for 2 years. No clinical renal and hepatic toxicity were documented, no biological toxicity was identifiable. Antigenemia remained negative, beta 2 microglobulin stable, T4 count stable, T4/T8 stable. The pyran appeared well tolerated. In these 10 cases, 8 patients remained free of any opportunistic infections, a clear enhancement of T4 count and T4/T8 ratio was observed in 1 patient. CONCLUSION: After two years, we evidenced the lack of both clinical and biological toxicity of pyran treatment on HIV-infected individuals after verification and control of the classical parameters of the HIV disease evolution. Pyran seems to have a positive impact on the immune system as seen on the T4 cells count. Pyran treatment has to be evaluated in a large double-blind clinical trial.
Publication Types:
Keywords:
- AIDS Vaccines
- Acquired Immunodeficiency Syndrome
- Adrenocorticotropic Hormone
- CD4-Positive T-Lymphocytes
- HIV Infections
- HIV Seropositivity
- Humans
- Hydrocortisone
- Thyroxine
- beta 2-Microglobulin
Other ID:
UI: 102205152
From Meeting Abstracts